Alert SJ, Pérez TM, Verdecia CC, Forteza SM, García SD, del Castillo BR

Language: Spanish
References: 20
Page: 1-10
PDF size: 280.65 Kb.

ABSTRACT

Introduction: Cardiotoxicity depends on various factors and it is evident in cardiovascular alterations induced by oncologic treatments directed to the heart´s function and morphology.
Objective: To determine the symptoms of cardiotoxicity in pediatric patients.
Methods: Descriptive and cross-sectional study in which there were included 79 patients treated in the Cuban Institute of Oncology and Radiobiology with thorax-mediastine irradiation from January 2008 to December 2014. Hodgkin disease was present in 54 patients, tumors of the central nervous system in 25, medulloblastomas in 19, and neuroectodermic primary tumors in 6. All the patients underwent physical examination, 12 –lead electrocardiogram and pre– and post-treatment 2D echocardiograms to include in the clinical records. The demographic and clinic characteristics were analyzed. Hodgkin disease’s patients received irradiation with 2 400 cGy intensity and the patients presenting tumors in the central nervous system with 2 340 cGy. Polychemotherapy was carried out with antracyclines, vincristine, vinblastine and others.
Results: Average age of all patients was 7 years with predominance of male sex. Symptoms of cardiotoxicity were not recorded.
Conclusions: In the serie of analyzed patients, irradiation in the heart area was apparently well beared by the patients, without early appearance of cardiotoxicity, not even in follow up periods of 9 years. Transitory nausea and leucopenia appeared in some cases. There are no differences in the toxicities of the different tumour’s groups studied. It is necessary to keep the regular follow up to rule out the appearence of cardiotoxicity in the next years.

REFERENCES

1. Bhatia SW, Blatt J, Meadows A. Late effects of childhooh cancer and its treatment. In: Pizzo PH, Poplak D, editors. Principles and practice of Pediatric Oncology. 5th ed. Phladelphia: Lippincott William and Wilkins; 2006. p. 1490-516.

2. 2.Kuchaska W, Negrusz-Kawaska M, Gromkowska M. Cardiotoxicity of oncological treatment in children. Adv Clin Exp Med. 2012;21:281-8.

3. Lipshultz E, Sambatalos P, Maguire M, Karnik R, Ross S, Franco V, et al. Cardiotoxicity and cardioprotection in childhood cáncer. Acta Haematol. 2014;32:391-9.

4. Currigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri M, et al. Cardiovascular toxicity induced by chemotherapy targeted agents and Radiotherapy. ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl.):155-66.

5. Welch GD, Lin KY, Fisher MJ, Hell-Kaiser CE. Cardiac toxicity after cranio espinal irradiation: a late effect that may be eliminated with proton therapy. J Pediatr Hematol Oncol. 2018; 40:330-3.

6. Aleman BMP, Moser EC, Nuver T, Suter M, Masaldo M, Specht L, et al. Cardiovascular disease after cancer therapy. Eur J Cancer. 2014; suppl 12:18-28.

7. Rosa GM, Gigli L, Tagliasacchi D, Di Lorio C, Carbone F, Nenciom A, et al. Update on cardiotoxicity of anticancer treatments. Eur J Clin Invest. 2016; 46: 264-82.

8. Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation induced cardiovascular disease. World J Cardiol. 2016;8:504-19.

9. Velazquez C, González M, Garcia-Orjuela M, Jaramillo N. Enfermedad cardiaca inducida por Radioterapia. Rev Colomb Cardiol. 2018;12:1-102.

10. Morales R, Sierra L, Triana A. Cardiotoxicidad inducida por quimioterapia. Cor Sald. 2018;10:68-77.

11. Zeng H, Kobrinsky B, Katzs S, Speyer J. Cardiac effects of cancer therapy. In: Abeloff S, editor. Abeloff’s Clinical Oncology, 5th ed. Philadelphia: Elsevier Saunders; 2014. p. 858-73.

12. Anuario Estadistico de Salud 2016. Dirección de Registros Médicos y Estadísticas de la Salud. La Habana: Ministerio de Salud Pública; 2017.

13. Anuario Estadistico de Salud 2015. Dirección de Registros Médicos y Estadísticas de la Salud. La Habana: Ministerio de Salud Pública; 2016.

14. Mulroony D, Amstrong G, Huang S, Ness K, Ehrhardt M, Joshi V, et al. Cardiacac outcome in adults survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Int Med. 2016;164:93-101.

15. Alert J, Chon I, Ropero R, Reno J, Verdecia C, Valdes J, et al. Valoración del tratamiento radiante en la enfermedad de Hodgkin en niños y adolescentes. Rev Cubana Pediatr. 2017;89(3):310-18. Acceso: 15/10/2018. Disponible en: http://scielo.sld.cu/pdf/ ped/v89n3/ped05317.pdf

16. Alert J, Chon I, Ropero R. Resultados del empleo de la Radioterapia en el tratamiento de los tumores del Sistema Nervioso Central en niños y adolescentes. Rev Cubana Pediatr. 2016:88(2):120-9. Acceso: 15/10/2018. Disponible en: http://scielo.sld.cu/pdf/ped/v88n2/ ped02216.pdf

17. Hudson M, Oncin M, Donaldson S. Hodgkin lymphoma, In: Pizzo PH, Poplak D, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott William & Wilkins; 2006. p. 722-47.

18. 18.Shankar R, Davies S. Lymphocitic predominant Hodgkin lymphoma in children and adolescents-a comprehensive review of biology, clinical course and treatment options. Brit J Haematol. 2015;159:288-98.

19. Amin A, Murphy B, Cost C, Garrington T, Graffe B, Liu K. Cardiac mortality in children and adolescents with Hodgkin’s lymphoma: a surveillance, epidemiology and end results analysis. J Adolescen Young Adults Oncol. 2016;5:181-6.

20. Blaney S, Kun L, Hunter J, Rorke-Adams L, Lau Ch, Strother D, et al. Tumors of the Central Nervous System. In: Pizzo PH, Poplak D, editors. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott William & Wilkins; 2006. p. 786-864.